Intel stock spikes after report of possible US government stake
Investing.com -- Rani Therapeutics Holdings Inc (NASDAQ:RANI) stock surged 18% after the clinical-stage biotherapeutics company announced it will present preclinical data on its RaniPill capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) in July 2025.
The presentation will focus on data demonstrating bioequivalence between oral delivery of a bispecific GLP-1/GLP-2 receptor agonist via Rani’s robotic pill technology and subcutaneous injection in canines. The poster presentation, titled "Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines," will be presented on July 14, 2025.
This announcement represents a potential advancement in Rani’s development of oral biologics delivery systems. The company’s technology aims to provide an alternative to injectable administration for biological drugs, which could potentially improve patient compliance and experience.
The presentation will take place during the session "Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II" at the conference in San Francisco.
Rani Therapeutics is focused on developing the RaniPill capsule, a platform technology designed to enable the oral delivery of biologics and drugs that are currently administered via injection.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.